40 Leukemia Clinical Trials in Bethesda, MD (2026)

Q: How do I join a clinical trial in Bethesda?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Bethesda research site will contact you.

Recruiting Leukemia Studies in Bethesda

NCT06732414Recruiting

A Biorepository of Multiple Allergic Diseases (MADREP) With Longitudinal Follow-Up

Background: Allergic or sinus diseases can affect the skin, sinuses, airways, and other parts of the body. Examples include pollen and environmental allergies, food allergies, asthma, and eczema. To ...

Bethesda, MD10,000 participantsNational Institute of Allergy and Infectious Diseases (NIAID)

View Study Details

NCT02146170Recruiting

Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors

Background: \- Lung cancer is the leading cause of cancer-related death worldwide. It causes more than one million deaths every year. Researchers want to gather tissue samples from people with lung a...

Bethesda, MD2,000 participantsNational Cancer Institute (NCI)

View Study Details

NCT02504853Recruiting

Natural History and Genetics of Food Allergy and Related Conditions

Background: \- About 15 million Americans have a food allergy. Because there are no cures or effective prevention or treatment for food allergies, researchers want to learn more about them. Objectiv...

Bethesda, MD1,800 participantsNational Institute of Allergy and Infectious Diseases (NIAID)

View Study Details

NCT01087333Recruiting

Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment

Background: \- Researchers who are studying hairy cell leukemia, and how the disease compares with other disorders, are interested in obtaining additional samples from leukemia patients and healthy v...

Bethesda, MD1,263 participantsNational Cancer Institute (NCI)

View Study Details

NCT01553214Recruiting

Improving White Blood Cell Collection From Healthy Donors

Background: \- White blood cells called granulocytes help the body fight infection. People who have had chemotherapy or bone marrow transplants may have very low numbers of these cells. Transfusions ...

Bethesda, MDPHASE41,000 participantsNational Institutes of Health Clinical Center (CC)

View Study Details

NCT00106925Recruiting

Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants

This study will provide follow-up evaluation and care of patients who have undergone allogeneic (donor) stem cell transplantation at the NIH Clinical Center. Patients are monitored for their response ...

Bethesda, MD1,000 participantsNational Heart, Lung, and Blood Institute (NHLBI)

View Study Details

NCT05254743Recruiting

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment...

Bethesda, MDPHASE3737 participantsLoxo Oncology, Inc.

View Study Details

NCT05131022Recruiting

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies....

Bethesda, MDPHASE1572 participantsNurix Therapeutics, Inc.

View Study Details

NCT07154823Recruiting

A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies

The TEMPUS AQUARIUS Study is a non-interventional, longitudinal observational study focused on hematological malignancies. It will collect rich molecular (multi-omic) and clinical data from patient co...

Bethesda, MD550 participantsTempus AI

View Study Details

NCT05099172Recruiting

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC), a group of lung cancers that have spread to nearby tissues or to other parts of the body....

Bethesda, MDPHASE1400 participantsBayer

View Study Details

NCT05645107Recruiting

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

The primary purpose of the study is to evaluate whether biweekly administered XEMBIFY® plus Standard Medical Treatment (SMT) over a one-year period will reduce the rate of major bacterial infections p...

Bethesda, MDPHASE3386 participantsGrifols Therapeutics LLC

View Study Details

NCT04959175Recruiting

Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

Background: Certain blood cancers can be treated with blood or bone marrow transplants. Sometimes the donor cells attack the recipient's body, called graft-versus-host disease (GVHD). The chemotherap...

Bethesda, MDPHASE1320 participantsNational Cancer Institute (NCI)

View Study Details

NCT07342478Recruiting

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

This is a Phase 3, randomized, open-label, multicenter study comparing rocbrutinib (LP-168) versus pirtobrutinib in adult participants with relapsed or refractory chronic lymphocytic leukemia (CLL) or...

Bethesda, MDPHASE3306 participantsNewave Pharmaceutical Inc

View Study Details

NCT05436418Recruiting

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

Background: Blood cancers (such as leukemias or lymphomas) often do not respond to standard treatments. A transplant of blood stem cells from a healthy donor can help people with these cancers. Somet...

Bethesda, MDPHASE1260 participantsNational Cancer Institute (NCI)

View Study Details

NCT06846671Recruiting

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

The purpose of this study is to investigate the efficacy and safety of BGB-16673 compared with investigator's choice (idelalisib plus rituximab \[for CLL only\] or bendamustine plus rituximab or venet...

Bethesda, MDPHASE3250 participantsBeiGene

View Study Details

NCT04068597Recruiting

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk M...

Bethesda, MDPHASE1250 participantsCellCentric Ltd.

View Study Details

NCT06588478Recruiting

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (S...

Bethesda, MDPHASE2249 participantsLoxo Oncology, Inc.

View Study Details

NCT04830137Recruiting

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies....

Bethesda, MDPHASE1248 participantsNurix Therapeutics, Inc.

View Study Details

NCT07613099Recruiting

Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging

Background: Injury or diseases of the heart and lung can sometimes cause scar tissue (fibrosis) to build up in those organs. Current imaging scans can see this scar tissue once it has formed, but res...

Bethesda, MDPHASE3210 participantsNational Heart, Lung, and Blood Institute (NHLBI)

View Study Details

NCT03835767Recruiting

Food-Specific and Component IgE Threshold Levels That Predict Food Allergy in People With Elevated Total Serum IgE Levels and Atopic Dermatitis

Background: Atopic dermatitis (AD), also called eczema, makes skin dry, red, and itchy. People with AD are more likely to get a food allergy than people without AD. But some food allergy tests are no...

Bethesda, MDPHASE2200 participantsNational Institute of Allergy and Infectious Diseases (NIAID)

View Study Details

NCT05724121Recruiting

Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax

Background: Bruton s tyrosine kinase inhibitors (BTKi) are used to treat a form of leukemia. But taking BTKi can also increase a person s risk of developing an abnormal heart rhythm. This can cause s...

Bethesda, MD135 participantsNational Heart, Lung, and Blood Institute (NHLBI)

View Study Details

NCT06364423Recruiting

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

Background: Chronic lymphocytic leukemia (CLL),small lymphocytic lymphoma (SLL) and B-cell acute lymphoblastic leukemia or lymphoma (ALL) are blood cancers that affect certain white blood cells. Adva...

Bethesda, MDPHASE1132 participantsNational Cancer Institute (NCI)

View Study Details

NCT07271381Recruiting

THREAT: Testing Harms Related to Exposure to Allergenic and Epithelial Toxins

Background: Allergic and inflammatory conditions have been increasing over the years. Many factors may play a role in this. Every day, people are exposed to pollution and chemicals in our foods, clot...

Bethesda, MDNA120 participantsNational Institute of Allergy and Infectious Diseases (NIAID)

View Study Details

NCT03907475Recruiting

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

This phase II trial studies the side effects of durvalumab when given together with chemotherapy in treating patients with solid tumors that have spread to other places in the body (advanced). Immunot...

Bethesda, MDPHASE2115 participantsNational Cancer Institute (NCI)

View Study Details

NCT06856226Recruiting

Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant

Background: After an allogeneic hematopoietic stem cell transplant (HSCT), the donor genome is found in the recipient s circulation and tissues. Post-HSCT recipients may receive a medication in whic...

Bethesda, MD88 participantsNational Cancer Institute (NCI)

View Study Details

NCT02133196Recruiting

T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

Background: The NCI Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the laboratory in large numbers, and then giving...

Bethesda, MDPHASE285 participantsNational Cancer Institute (NCI)

View Study Details

NCT06965114Recruiting

Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia

This phase I/II trial tests the safety, side effects, and effectiveness of tovorafenib in combination with rituximab in patients with classical hairy cell leukemia (cHCL) that has come back after a pe...

Bethesda, MDPHASE184 participantsNational Cancer Institute (NCI)

View Study Details

NCT03986034Recruiting

Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Background: The drug venetoclax treats chronic lymphocytic leukemia (CLL). Researchers want to find better treatments for CLL. To do that, they need to learn how the drug affects CLL cancer cells and...

Bethesda, MDPHASE275 participantsNational Heart, Lung, and Blood Institute (NHLBI)

View Study Details

NCT06161532Recruiting

Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...

Background: Rare tumors of the genitourinary (GU) tract can appear in the kidney, bladder, ureters, and penis. Rare tumors are difficult to study because there are not enough people to conduct large ...

Bethesda, MDPHASE260 participantsNational Cancer Institute (NCI)

View Study Details

NCT05621291Recruiting

A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...

Background: Chimeric antigen receptor T-cell (CART) therapy is a form of immunotherapy which can be used to treat people with relapsed B-ALL. For those who achieve remission after CART alone, it may ...

Bethesda, MDNA60 participantsNational Cancer Institute (NCI)

View Study Details

NCT06694454Recruiting

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Background: Lung cancer is the leading cause of cancer-related death worldwide. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Surgery to remove the tumors is the standard...

Bethesda, MDPHASE160 participantsNational Cancer Institute (NCI)

View Study Details

NCT06228066Recruiting

Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)

Background: Small cell carcinoma of the bladder (SCCB) and other high-grade neuroendocrine tumors (HGNET) of the urinary tract are rare but aggressive cancers. Average survival for people diagnosed w...

Bethesda, MDPHASE245 participantsNational Cancer Institute (NCI)

View Study Details

NCT06093867Recruiting

Early Detection of Infectious and Noninfectious Lung Diseases Following Allogeneic Hematopoietic Stem Cell Transplantation

Background: Stem cell transplants (called hematopoietic stem cell transplantation, or HSCT) are used to treat various diseases. But when the cells for this procedure are donated by someone other than...

Bethesda, MD40 participantsNational Heart, Lung, and Blood Institute (NHLBI)

View Study Details

NCT04322383Recruiting

Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant

Background: Most people with hairy cell leukemia have a BRAF gene mutation. They can be treated with BRAF inhibitors, drugs that target this mutation. For people who do not have this mutation, BRAF i...

Bethesda, MDPHASE240 participantsNational Cancer Institute (NCI)

View Study Details

NCT06066138Recruiting

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Background: A type of drug called monoclonal antibody immune checkpoint inhibitors are often used in cancer treatment. These drugs help the body s immune system fight cancer by blocking proteins that...

Bethesda, MDPHASE130 participantsNational Cancer Institute (NCI)

View Study Details

NCT07428707Recruiting

Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib

Background: Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are blood cancers that affect certain white blood cells. Advanced forms of these diseases are difficult to treat. P...

Bethesda, MDEARLY_PHASE130 participantsNational Heart, Lung, and Blood Institute (NHLBI)

View Study Details

NCT04815356Recruiting

Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant

Background: CAR (Chimeric Antigen Receptor) T cell therapy is a type of cancer treatment in which a person s T cells (a type of immune cell) are changed in a laboratory to recognize and attack cancer...

Bethesda, MDPHASE127 participantsNational Cancer Institute (NCI)

View Study Details

NCT05777603Recruiting

Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer

Background: Non-small cell lung cancer (NSCLC) can be hard to treat and is often fatal. People with NSCLC commonly have changes in the bacteria that populate their lungs. These bacterial changes may ...

Bethesda, MDPHASE123 participantsNational Cancer Institute (NCI)

View Study Details

NCT07328503Recruiting

CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Background: Acute lymphoblastic leukemia (ALL) is a type of blood cancer. Chimeric antigen receptor (CAR) therapy involves taking immune cells (T cells) from a person and modifying them to better tar...

Bethesda, MDPHASE220 participantsNational Cancer Institute (NCI)

View Study Details

NCT05642455Recruiting

SPEARHEAD-3 Pediatric Study

This is a pediatric basket study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A\*02 eligible and MAGE-A4 positive subjects aged 2-17 years of age with advanced cancers....

Bethesda, MDPHASE120 participantsAdaptimmune

View Study Details

About Leukemia Clinical Trials in Bethesda

Leukemia is a group of blood cancers that develop in the bone marrow and result in abnormal white blood cells. Types include acute myeloid (AML), acute lymphoblastic (ALL), chronic myeloid (CML), and chronic lymphocytic (CLL). Treatment varies by type and may include chemotherapy, targeted therapy, and stem cell transplant.

There are currently 40 leukemia clinical trials recruiting participants in Bethesda, MD. These studies are seeking a combined 23,290 participants. Research is being sponsored by National Institute of Allergy and Infectious Diseases (NIAID), National Cancer Institute (NCI), National Institutes of Health Clinical Center (CC) and 10 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Leukemia Clinical Trials in Bethesda — FAQ

Are there leukemia clinical trials in Bethesda?

Yes, there are 40 leukemia clinical trials currently recruiting in Bethesda, MD. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Bethesda?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Bethesda research site will contact you about next steps.

Are clinical trials in Bethesda free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Bethesda studies also compensate for your time and travel.

What leukemia treatments are being tested?

The 40 active trials in Bethesda are testing new therapies including novel drugs, biologics, and treatment approaches for leukemia.

Data updated July 18, 2026 from ClinicalTrials.gov